Market Overview:

According to IMARC Group’s latest research publication, “Syphilis Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2034”, The global syphilis testing market reached USD 1.34 Billion in 2025 and is projected to reach USD 2.07 Billion by 2034, exhibiting a CAGR of 4.82% during 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How Syphilis Testing Is Transforming Global Infectious Disease Diagnostics

• Primary and secondary syphilis testing leads the type segment with a 58.4% market share in 2025, driven by acute epidemic burden, partner notification protocols, and active case-finding programs across STI clinics and public health systems.
• Laboratory testing dominates the location segment at 66.9% in 2025, as automated chemiluminescence immunoassay platforms enable high-throughput reverse algorithm testing for antenatal screening, blood donor testing, and hospital-based STI protocols.
• In 2026, Abbott received WHO prequalification for its Determine Syphilis Advanced rapid test, adding a newer syphilis diagnostic to its globally prequalified product portfolio and strengthening access to point-of-care testing in low- and middle-income countries.
• In March 2025, bioLytical Laboratories launched its INSTI Multiplex HIV-1/2 Syphilis Antibody Test in Australia following inclusion in the Australian Register of Therapeutic Goods, delivering dual rapid results in approximately 60 seconds.
• North America commands 39.1% of global market share in 2025, reflecting the unprecedented US syphilis epidemic burden, with nearly 4,000 congenital syphilis cases reported in 2024 alone, marking the 12th consecutive year of increasing infections.

Download a sample PDF of this report: https://www.imarcgroup.com/syphilis-testing-market/requestsample

Key Trends in the Syphilis Testing Market

• Resurgent Syphilis Epidemic Creating Sustained Testing Demand: The United States reported nearly 4,000 cases of congenital syphilis in 2024, rising by nearly 2% compared with 2023. Mississippi has experienced an 80% rise in syphilis cases and a 1,000% increase in congenital infections over the past six years. In Hungary, congenital syphilis caused the deaths of more than 20 infants in 2025. These alarming statistics are compelling governments, hospitals, and STI clinics to expand routine and prenatal syphilis screening, directly driving test volume growth across laboratory and point-of-care settings.
• Chemiluminescence Immunoassay Technology Replacing Manual Testing: Laboratories are progressively replacing manual enzyme immunoassay and RPR methods with automated chemiluminescence immunoassay platforms that support the reverse syphilis testing algorithm. These systems deliver turnaround times of under two hours for complete syphilis workups, support random-access testing without batch accumulation, and improve analytical throughput. In January 2025, Anbio Biotechnology introduced the ADL-1000 Dry Chemiluminescence Immunoassay Solution, providing fast, accurate, and cost-effective diagnostics for clinical laboratories.
• Multiplex STI Panel Integration Expanding Syphilis Detection: Healthcare providers are adopting multiplex molecular assay panels that detect syphilis alongside HIV, gonorrhea, chlamydia, trichomoniasis, and hepatitis within a single testing workflow. These integrated panels reduce turnaround time, improve diagnostic efficiency, and support faster treatment decisions. As STI co-infection rates rise, multiplex testing is increasing the total number of syphilis tests ordered per patient encounter, including in populations not previously prioritized for standalone syphilis screening.
• Point-of-Care Rapid Testing Adoption Growing in Community Settings: Demand for rapid syphilis point-of-care tests is growing across primary care facilities, emergency departments, antenatal clinics, correctional health programs, and community health centers. These portable devices enable same-visit diagnosis and treatment without laboratory infrastructure, reducing patient loss to follow-up. POC testing holds 33.1% of the location segment in 2025 and is growing at a faster pace than laboratory testing, particularly in Asia-Pacific and sub-Saharan African settings supported by global dual elimination antenatal programs.
• Home-Based Syphilis Self-Testing Emerging as a New Delivery Channel: Companies are investing in home collection and self-testing platforms that expand access to syphilis screening in high-risk and underserved populations. In September 2025, Tia Health partnered with Molecular Testing Labs to provide an FDA-cleared at-home specimen collection kit for simultaneous STI screening. Using Abbott’s simpli-COLLECT STI Test, patients can collect samples at home and receive results through their healthcare provider for chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium, with syphilis co-screening pathways expanding concurrently.

We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging syphilis testing market trends. 

Growth Factors in the Syphilis Testing Market

• Mandated Antenatal Screening Driving Structural Test Volume Growth: The congenital syphilis crisis in North America has prompted mandatory third-trimester syphilis screening legislation across multiple US states, compelling obstetrics practices, hospital laboratories, and antenatal clinics to incorporate syphilis testing into standard prenatal care protocols. These policy mandates generate recurring, policy-sustained test volume that represents a durable demand floor extending through the forecast period regardless of whether case counts respond to public health interventions.
• WHO Dual Elimination Initiative Creating LMIC Procurement Programs: The WHO global initiative to eliminate mother-to-child transmission of HIV and syphilis is driving structured national antenatal syphilis testing programs across more than 80 participating countries. These programs establish sustainable laboratory and point-of-care testing infrastructure, create large-volume tender-based procurement markets for rapid treponemal tests, and generate recurring reagent demand that anchors long-term market growth in regions with the highest disease burden.
• Asia-Pacific Infrastructure Investment and Screening Scale-Up: Asia-Pacific accounts for 21.6% of the global market in 2025 and represents the fastest-growing regional segment. China’s national syphilis epidemic response program, India’s antenatal screening scale-up, and Southeast Asian government-funded high-risk population testing initiatives are expanding both laboratory and point-of-care testing volume. Growing healthcare infrastructure investment, rising STI awareness, and increasing access to affordable rapid diagnostics are collectively supporting the region’s above-average growth trajectory.
• Blood Bank Donor Screening Providing Baseline Institutional Demand: Syphilis testing of all blood donations is mandated across North America, Europe, and a growing number of countries in Asia-Pacific and Latin America, creating a stable, policy-guaranteed minimum test volume that is independent of disease incidence fluctuations. The expansion of blood banking capacity in emerging economies and the modernization of blood bank testing with automated CLIA platforms are gradually increasing the total institutional demand for high-sensitivity treponemal screening assays.
• Emergency Department Universal Syphilis Screening Expansion: Driven by the extraordinary epidemic burden in the United States, leading academic medical centers and hospital systems are implementing universal opt-out syphilis screening in emergency departments, targeting populations with limited primary care engagement who otherwise would not receive routine STI screening. This transformation of emergency medicine testing protocols is expanding syphilis testing from specialty STI clinic services into mainstream hospital diagnostics, materially broadening the commercial market’s total addressable testing volume.

Leading Companies Operating in the Global Syphilis Testing Industry:

• Abbott
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.

Syphilis Testing Market Report Segmentation:

Breakup by Type:

• Primary and Secondary Syphilis
• Latent and Tertiary Syphilis

Primary and secondary syphilis testing leads at 58.4% in 2025, reflecting the highest-infectivity phase’s public health priority and the concentrated epidemic burden that generates the most urgent acute testing demand across STI clinics, emergency departments, and partner notification programs.

Breakup by Location of Testing:

• Laboratory Testing
• Point-of-Care (POC) Testing

Laboratory testing dominates at 66.9% in 2025 through the adoption of automated chemiluminescence immunoassay platforms that enable high-volume reverse algorithm testing in hospital core laboratories, reference laboratories, public health state laboratories, and blood bank environments.

Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads with 39.1% of global market share in 2025, driven by the unprecedented US syphilis epidemic, mandatory congenital syphilis prevention screening mandates, and the widespread adoption of automated laboratory testing platforms. Europe holds 28.3%, supported by routine prenatal testing and established laboratory networks. Asia-Pacific accounts for 21.6%, growing at the fastest regional pace through healthcare infrastructure expansion and government-led screening initiatives.

Recent News and Developments in the Syphilis Testing Market

• 2026: Abbott received WHO prequalification for its Determine Syphilis Advanced rapid test, further expanding its globally prequalified syphilis diagnostic portfolio and supporting access to accurate point-of-care testing in low- and middle-income countries with high antenatal syphilis burden.
• March 2025: bioLytical Laboratories launched its INSTI Multiplex HIV-1/2 Syphilis Antibody Test in Australia following inclusion in the Australian Register of Therapeutic Goods. The dual rapid test delivers both HIV and syphilis antibody results in approximately 60 seconds, enabling healthcare professionals to accelerate diagnosis and connect patients with appropriate care more quickly.
• January 2025: Anbio Biotechnology introduced the ADL-1000 Dry Chemiluminescence Immunoassay Solution, designed to provide fast, accurate, and cost-effective diagnostic testing for clinical laboratories, supporting the growing adoption of automated immunoassay platforms in the syphilis testing workflow.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201-971-6302